ライフサイエンスコーパス: treat

1 come, and analysis was based on intention to treat.

2 ory disease that is difficult to predictably treat.

3 Data were analyzed based on intention to treat.

4 uciating pain, which has proven difficult to treat.

5 her PSA increase in 65% (22/34) in those not treated.

6 ea of proximal skin necrosis were surgically treated.

7 large-cell lymphoma who had been previously treated.

8 dly recognized and adequately managed can be treated.

9 , and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with pla

10 abandoned antibiotic could be used again to treat a minority of gonorrhoea cases without raising res

11 CRISPR/Cas9 holds immense potential to treat a range of genetic disorders.

12 till considered a single disease and usually treated according to the "one-size-fits-all" approach.

13 gastric bypass with those of conservatively treated adolescents and of adults undergoing Roux-en-Y g

14 plication of targeting JAK for ALK- ALCL, we treated ALK- cell lines of various histological origins

15 ease is required to effectively consider and treat all patients with cardiovascular disease.

16 itis C virus-infected policy 1, "universal," treat all patients, regardless of fibrosis stage; policy

17 g this molecule could be a novel approach to treat allergic asthma.

18 ) were included in the modified intention-to-treat analysis (mean age, 52 [SD, 14] years; 75 women [3

19 ived treatment were included in an intent-to-treat analysis of the response rate.

20 Intention-to-treat analysis using mixed linear models showed that PBT

21 A 2 x 2 factorial intention-to-treat analysis with the use of a generalized mixed-effec

22 s log-transformed for analysis (intention-to-treat analysis).

23 In intent-to-treat analysis, there was a trend for prebiotic suppleme

24 n were included in the modified intention-to-treat analysis.

25 ll of whom were included in the intention-to-treat analysis.

26 related macular degeneration (nAMD) from the TReat and extEND (TREND) study.

27 his prospective, randomized trial found that treat and extend dosing of ranibizumab 0.3 mg with and w

28 nd mortality were estimated for intention-to-treat and per-protocol analyses.

29 ents occurred in 1.1% and 4.2% of everolimus-treated and CNI-treated patients, respectively, by month

30 (FDPs), with 1 healthy and 1 endodontically treated and fiber post-restored abutment.

31 dels of commensal colonization in antibiotic-treated and germ-free mice, using cultured commensals fr

32 ength of the heat-treated, impregnation/heat-treated and hydrothermal-treated samples were about 11.5

33 issues identified differences between EBOTAb-treated and untreated groups.

34 e., control, heat-treated, impregnation/heat-treated, and hydrothermal-treated samples.

35 he efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patien

36 w the improved phenotype of the Cu(II)(atsm)-treated animals involves an increase in mature mutant SO

37 d complement-mediated bacteriolysis, whereas treated animals showed slightly improved bacterial clear

38 ules that could serve as new drug targets to treat APOL1-associated renal diseases.

39 of labeled carbon into microbial biomass are treated as degradation products.

40 vistic thermodynamics is a topic that can be treated as part of an undergraduate course of classical

41 Phenological data have generally been treated as purely temporal, with scant attention to the

42 Supernatants from rPrP(c)-treated astrocytes containing factors produced in respon

43 overall response rate for patients with IMT (treated at 100, 165, and 280 mg/m(2)/dose) was 86%.

44 Methods Two-year HCT survivors treated at a comprehensive cancer center from 1992 throu

45 ive-year OS was 86.8% and 78.8% for patients treated at GR and at MSKCC, respectively (P < 0.01).

46 Despite an increased travel burden, patients treated at high-volume centers had improved perioperativ

47 ing of 182 patients with POAML, diagnosed or treated at our institution to analyze long-term outcome,

48 spital outcomes were compared among patients treated at outlier hospitals before and after public rep

49 the spleen; this was not evident among mice treated at ZT14.

50 ng its potential as a therapeutic target for treating autoimmune diseases.

51 R with conscious sedation on an intention-to-treat basis for the primary outcome of in-hospital morta

52 Leukocytes in CSWB-treated blood exhibited significantly higher viability a

53 Among hospitalized Medicare beneficiaries treated by a general internist, there were no significan

54 ng Miller Class I and II GRs were previously treated by CTG (control group; n = 20) or CTG + LLLT (te

55 ing flow cytometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 m

56 verall 30-day mortality rates among patients treated by locum tenens compared with non-locum tenens p

57 blished reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of th

58 erved that LLC cell-conditioned medium (LCM)-treated C2C12 myotubes underwent a rapid catabolic respo

59 TEC exposed to media conditioned by drug-treated CAFs exhibited a decrease in oncogenic signaling

60 vitamin K supplementation can prevent and/or treat calciphylaxis requires further study.

61 ards (NF-kappaB, Bcl-2 and p53) in these NPs-treated cancer cells compared to 5-fluorouracil (5-FU) t

62 Methotrexate-treated cancer survivors had significantly lower cerebra

63 .Significance: Illustrating the challenge in treating cancers with targeted drugs, which by selecting

64 Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unk

65 e IgE binding properties of pastes made from treated cashew and pistachio nuts.

66 enuated PGE2 and IL-6 release in HG+IL-1beta-treated cells than in NG+IL-1beta-treated cells.

67 es upon stimulation with aminobisphosphonate-treated cells.

68 ncer cells compared to 5-fluorouracil (5-FU) treated cells.

69 G+IL-1beta-treated cells than in NG+IL-1beta-treated cells.

70 erged as a promising therapeutic approach to treat cognitive deficits.

71 Observational intent-to-treat cohort analysis using the Veterans Affairs Clinica

72 R reverted the assembly of FN induced by MGO-treated collagen.

73 platin is instead used almost exclusively to treat colorectal and other gastrointestinal cancers.

74 y of fosfomycin as step-down oral therapy to treat complicated urinary tract infections.

75 Adipogenesis is induced by treating confluent preadipocytes with the adipogenic coc

76 ,000, US$76,000) per QALY gained, 50% Test & Treat coverage could avert up to 6,700 (95% CI: 1,200, 1

77 biological and evolutionary theory, but also treats culture as more than a proximate mechanism that i

78 ular trafficking studies of HIV-1 in cocaine treated DCs revealed increased co-localization of HIV-1

79 nd decreased degradation of HIV-1 in cocaine treated DCs.

80 are some of the latest options available for treating DED.

81 ment of clinical rehabilitation therapies to treat disabilities and complications of SCI.

82 -concept that this technology can be used to treat disease caused by epigenetic silencing of specific

83 ence of interest in using diet to manage and treat DM has emerged in recent years.

84 hundreds of thousands of patients with nAMD treated each year worldwide.

85 CSs treated in the 1990s compared with those treated earlier.

86 evaluation with the FAST examination by the treating ED physician or a standard trauma evaluation al

87 s (wild, agricultural, and domesticated) and treated effluent (n = 233) was used to generate a fecal

88 gamma-band network oscillations, and allowed treated eFSE rats to encode and retrieve spatial memorie

89 CD14(+) monocytes treated either with recombinant human IFN-gamma or with

90 ected by targeting Stard7 to mitochondria or treating epithelial cells with a mitochondrial-targeted

91 using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has co

92 We treated exposure as time-varying when it was updated ann

93 ser microdissected in placebo- and sulindac- treated FAP patient tissue after which the methylation p

94 patients, 259 treated for 1-3 days and 1031 treated for >3 days.

95 There were 1290 eligible patients, 259 treated for 1-3 days and 1031 treated for >3 days.

96 e was observed during follow-up in a patient treated for 6 months.

97 Being diagnosed with and treated for cancer is highly stressful and potentially t

98 ively collected data on CHCs in all patients treated for childhood cancer at the St Jude Children's R

99 Conclusion Women previously treated for depression constitute a large subgroup of pa

100 Of 497 patients treated for HCV, 257 achieved SVR and had at least 1 sub

101 clusion as age-matched controls if they were treated for lymphoma, received combination chemotherapy,

102 burden states for clinically diagnosed cases treated for MDR-TB.

103 dies (n = 39211) included cohorts of persons treated for well-differentiated thyroid cancer and perso

104 tors application for active drug delivery to treat gastric bacterial infection in a mouse model using

105 in research and clinical area to effectively treat gliomas by reaching a high antineoplastic drug con

106 icantly higher (P = .001) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n

107 % lower Salmonella carriage is measured in a treated group, 14 days post-Salmonella challenge.

108 ue thickness gain was significant only in CM-treated groups (P <0.05).

109 First and foremost, treating hearing loss should be investigated as a means

110 T cells isolated from TAC-treated hearts show enhanced production of proinflammato

111 In GS-967-treated hearts, significantly more spontaneous terminati

112 Efforts to identify pharmaceuticals to treat heritable metabolic liver diseases have been hampe

113 We treat heterogeneity as a latent class allocation problem

114 ive immunologic interventions to prevent and treat HIV-1 infection, standardized reference reagents a

115 scervical inoculation of medroxyprogesterone-treated HLA-DR4 transgenic mice with 5 x 10(5)C. trachom

116 Only TLN-treated human endothelial cells and neonatal porcine isl

117 defects, strongly predicts mortality during treated human immunodeficiency virus (HIV) disease in Ug

118 Unsuccessfully treated hypertension was defined as daytime ambulatory B

119 offers an innovative therapeutic target for treating hypoxic-ischemic human diseases and organ trans

120 duction of the flexural strength of the heat-treated, impregnation/heat-treated and hydrothermal-trea

121 re sorted into 4 groups, i.e., control, heat-treated, impregnation/heat-treated, and hydrothermal-tre

122 roidism, and dementia, and less likely to be treated in a facility with an observation unit.

123 al cohort of patients with lymphoma who were treated in a randomised trial of front-line chemotherapy

124 All tumors were treated in a single procedure using the 4C or Perfexion

125 psed or refractory multiple myeloma who were treated in clinical trials with IMiD-containing regimens

126 , but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstrating a reve

127 clusion Patients with breast cancer who were treated in community oncology clinics report substantial

128 Moreover, CR+ interneurons are often treated in models as a single homogenous population, des

129 6%) and did not change noticeably among CCSs treated in the 1990s compared with those treated earlier

130 astatic to the abdominal viscera in patients treated in the modern treatment environment.

131 lood mononuclear cells from HIV-infected ART-treated individuals in response to M. tuberculosis antig

132 antibiotics are prescribed appropriately to treat infections, there continue to be a large number of

133 n is a promising strategy for preventing and treating IR-induced liver damage.

134 , 6600 of the diabetic patients were insulin treated (IT).

135 that target Bcl-2 are used in the clinic to treat leukemia, but tight and selective inhibitors are n

136 Brentuximab vedotin is effective in treating LyP (overall response rate, 100%; complete resp

137 mpanied by augmented PV degradation in Wnt5a-treated macrophages was also apparent from transmission

138 nd in the safety analysis in an intention-to-treat manner.

139 Ultrastructural analysis of MMP-3 treated matrices by transmission electron microscopy rev

140 -beta remained practically unaffected in ImI treated MDMs.

141 ant change in prostate cell proliferation in treated mice when compared to controls.

142 ls and an expansion of sequence diversity in treated mice.

143 PT1/2 phosphorylation seen only in TRV120067-treated mice.

144 (31.2 +/- 1.0% vs. 24.7 +/- 2.2% in vehicle-treated mice; p < 0.05) but not in the RA CMC group (24.

145 al contrast among biological tissues and can treat microvessels without causing collateral damage to

146 The overall intent-to-treat minimal residual disease-negative (MRD(-)) remissi

147 This increased accumulation for HA-treated MSC yielded a substantial reduction in inflammat

148 ration could help inform research efforts to treat muscle diseases or improve muscle function.

149 nstream phenotypic consequences in sudemycin-treated mutant cells.

150 ghlight the promise of bariatric surgery for treating NASH and underscore the need for clinical trial

151 MP-3, MMP-9, MMP-13 and ADAMTS-4 in IL-1beta-treated OA chondrocytes.

152 ith prebiotics or other agents to prevent or treat obesity.

153 2A agonist activities, which is approved for treating obesity.

154 In methadone-treated OD subjects drawn from a case and control sample

155 nts, regardless of fibrosis stage; policy 2, treat only "prioritized" patients, delay treatment of th

156 that, in clinical practice, lansoprazole can treat or prevent incident tuberculosis (TB) disease.

157 ng of 144 single LNCaP prostate cancer cells treated or untreated with androgen after cell-cycle sync

158 e is no effective pharmacologic approach for treating or preventing AKI.

159 We treated our patient with ustekinumab, an antibody that b

160 Finally, as with many trials, some placebo-treated participants showed improvement on the SRS.

161 agonist aripiprazole is increasingly used to treat pathologies for which other antipsychotics are ind

162 To treat patients suffering from such viral infections, bro

163 It is a challenge to treat patients with cirrhosis using anticoagulants, beca

164 ported in 41 of 195 medically and surgically treated patients (21%) with glaucoma.

165 events were reported in 56 (58%) eltrombopag-treated patients and 32 (68%) placebo-treated patients.

166 Focused analyses with aminoglycoside-treated patients are needed next to evaluate a possible

167 st 25 years, and its cure in the majority of treated patients is one of the greatest achievements in

168 Median overall survival was not reached for treated patients overall; all responders were still aliv

169 A significantly larger percentage of treated patients survived to 18 months of follow-up, com

170 Among treated patients the CoA segment (the maxillary length)

171 Two hundred and twenty FRALLE2000T-treated patients were tested retrospectively for NOTCH1/

172 tly reduced rates of relapse in lestaurtinib-treated patients who achieved sustained greater than 85%

173 1.1% and 4.2% of everolimus-treated and CNI-treated patients, respectively, by month 12 (P = 0.018)

174 mbopag-treated patients and 32 (68%) placebo-treated patients.

175 caspofungin therapy when compared with azole-treated patients.

176 intermediate between that of controllers and treated patients.

177 l printing ink is developed and printed onto treated PDMS with no visible signs of delamination and g

178 These results are promising for treating PFOA-contaminated water and demonstrate the ver

179 nd identify potential "drivers," so that the treating physician can prioritize what clinical decision

180 patients were excluded from the intention-to-treat population (3 had overt distant metastases at the

181 int was overall survival in the intention-to-treat population and safety was assessed in all patients

182 s was a post hoc analysis of an intention-to-treat population of 270 patients who underwent (68)Ga-PS

183 rom any cause), analysed in the intention-to-treat population.

184 ry Naming Test) in the modified intention-to-treat population.

185 icacy analyses were done in the intention-to-treat population.

186 l analyses were conducted in an intention-to-treat population.

187 Outcomes were analyzed on the intention-to-treat-population with the use of baseline-carried-forwar

188 r the development of therapies to prevent or treat postoperative cognitive dysfunction and other form

189 associated with differences in efficacy for treating prescription opioid dependence, and is long-ter

190 eveloped to treat schizophrenia, are used to treat psychosis, agitation and aggression in Alzheimer's

191 This phenotype was not observed in Ig-treated Rag1(-/-) mice or wild-type mice treated with an

192 was significantly reduced in the RVM of CFA-treated rats compared with naive rats.

193 Treating rats with decitabine either during LT-IH or dur

194 ther dying, untreated rods negatively impact treated, rescued rods.

195 a-peritoneal (i.p.) chemotherapy effectively treats residual EOC after cyto-reduction by gaining dire

196 ides a paradigm for developing strategies to treat respiratory distress in SMA.

197 efficacy and safety of 2 sclerosants used to treat reticular veins: 0.2% polidocanol diluted in 70% h

198 Three patients with treated retinoblastoma who developed severe PVR and requ

199 tion being physician-diagnosed and medically treated RW up to 13 months of age.

200 CSWB-treated samples showed a significant improvement in eryt

201 , impregnation/heat-treated and hydrothermal-treated samples were about 11.57%, 8.53% and 15.90%, res

202 impregnation/heat-treated, and hydrothermal-treated samples.

203 antly reduced after application of thermally-treated samples.

204 Antipsychotic drugs, originally developed to treat schizophrenia, are used to treat psychosis, agitat

205 Such effects were not observed in paroxetine-treated SERT (-/-) mice.

206 Aged rats treated ST or LT with FKBP1b substantially outperformed

207 ndomised controlled trial of an HIV test-and-treat strategy in 32 rural communities in Uganda and Ken

208 mics is a potential therapeutic approach for treating stress-induced behavioral disorders, and that d

209 The use of levothyroxine to treat subclinical hypothyroidism is controversial.

210 od samples from both omalizumab- and placebo-treated subjects.

211 ASDH cases in the adult population (>16 yrs) treated surgically between 1994 and 2013.

212 ay represent peripherally available drugs to treat tactile-driven pain following neuropathy.

213 ignificant differences were observed between treated teeth (T1) and their contralateral, both buccal-

214 It is tougher to treat than most strains of Staphylococcus aureus or stap

215 ly higher fluorescence signal from (18)F-FDG-treated than untreated cells.

216 l acting antibacterials is in development to treat the rising threat of antimicrobial resistance, par

217 tem cells (hMSCs) is an emerging therapy for treating the failing heart.

218 ivity of the check-all-that-apply questions, treating the forced-choice format as the "gold standard,

219 Understanding and treating this disease remains a challenge, as seizures m

220 ced immunosuppression amongst mice that were treated topically with available anti-cancer drugs (imiq

221 diverse UPEC isolates, while simultaneously treating UTI, without notably disrupting the structural

222 rbon footprint per cubic meter of wastewater treated, varies markedly with the carbon substrate.

223 ells has emerged as a promising approach for treating various cancers and chronic infections.

224 ICD-treated VT/VF was associated with NSVT runs at a rate >2

225 Analysis of the postdisinfected treated wastewater showed the presence of clinically rel

226 of study drug, with treatment assignment as treated, were included in the safety analysis.

227 MRSA is particularly difficult to treat when it invades host cells and survive inside the

228 Treated white wines were analyzed for protein and phenol

229 For XPB, dentin was etched and treated with 0.3 M EDC for 1 min and then bonded with th

230 They were treated with 3-drug induction chemotherapy (vincristine,

231 Fellow eyes (n = 207) were treated with 5-minute dosing and considered in the safet

232 n anti-CD20 antibody-containing regimen were treated with 560 mg ibrutinib orally once daily until pr

233 henomenon was corroborated when WT mice were treated with a CB2-specific antagonist that caused a pro

234 enitor proliferation, is interrupted in mice treated with a hedgehog (Hh) pathway inhibitor (HPI), an

235 P2X7(-/-) mice and mice treated with a P2X7 inhibitor were protected from diabet

236 Finally, patients treated with a partial nephrectomy had reduced risk of m

237 Airway smooth muscle treated with activated mast cell supernatants produced e

238 new allergen sensitizations between patients treated with AIT and pharmacotherapy.

239 les with adult cerebral adrenoleukodystrophy treated with allogeneic haematopoietic stem cell transpl

240 rombectomy patients and 132 matched controls treated with alteplase alone.

241 Because more patients are being treated with alternative programs, comparison of results

242 HUVECs were treated with and without palmitate in the presence or ab

243 two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we f

244 presses the estrogen receptor (ER(+)) and is treated with anti-estrogen therapies, particularly tamox

245 Ig-treated Rag1(-/-) mice or wild-type mice treated with anti-type I IFNR alone.

246 significantly higher proportion of patients treated with anticoagulants underwent PVT recanalization

247 imately 38%) colonized only by S. aureus and treated with appropriate antibiotic for at least 2 days

248 e Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes

249 NOD mice treated with AZD1480 were protected from autoimmune diab

250 g-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gend

251 ed with an increased risk of AST in patients treated with bivalirudin but not patients treated with h

252 rolled adults with cirrhosis awaiting LT and treated with bridging or down-staging therapies before L

253 Cross-tolerance, in which plants pre-treated with chitin (a fungal microbe-associated molecul

254 nts within the wound beds compared to wounds treated with chitosan scaffolds containing control DNA o

255 Purpose Survivors of childhood cancer treated with cranial radiation therapy are at risk for s

256 dispensable for liver tumorigenesis in mice treated with DEN, and identifies an important role for A

257 Fifty-three men treated with docetaxel for mCRPC were tested for somatic

258 ications in acute coronary syndrome patients treated with extracorporeal circulatory support.

259 100% of the gadolinium species found in rats treated with gadoteridol.

260 ts treated with bivalirudin but not patients treated with heparin plus GPI, possibly because of the r

261 Fish treated with higher dietary Se doses (32.5 and 57.5 mug

262 n in freshly isolated mitochondria from mice treated with Honokiol showed enhanced mitochondrial resp

263 antle cell lymphoma cell lines, and patients treated with idelalisib, but not ibrutinib, showed incre

264 DPSCs treated with IFN-gamma and supplemented with pyrrolidine

265 e outcome of patients with advanced-stage FL treated with immunochemotherapy.

266 hTNF-Tg mice treated with infliximab demonstrated significant clinica

267 Type 1 diabetes treated with insulin pump therapy or with multiple (>/=4

268 /hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ribavirin (RBV), betwe

269 se-modifying activity, even if some patients treated with interferon and ruxolitinib showed reduction

270 reated with ocrelizumab and in 2.9% of those treated with interferon beta-1a.

271 s in patients with displaced tibial fracture treated with intramedullary nail fixation vs locking pla

272 th coma (Glasgow Coma Scale score </= 8) and treated with invasive mechanical ventilation.

273 IDA patients can be treated with iron supplementation, yet TT patients have

274 omen taking </=5 mg warfarin daily and women treated with LMWH.

275 were compared among eight patients who were treated with methotrexate and eight untreated age-matche

276 with birth weight less than 1,251 g who were treated with neonatal caffeine had improved respiratory

277 d with the development of PML in MS patients treated with NTZ.

278 Furthermore, articular chondrocytes treated with OA derived extracellular vesicles had decre

279 s infection occurred in 1.3% of the patients treated with ocrelizumab and in 2.9% of those treated wi

280 ll survival to hospital discharge after OHCA treated with PAD showed a median survival of 40.0% (rang

281 Eleven women were treated with pdC1-INH for 143 facial attacks.

282 Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up

283 s with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 mug (V

284 on at 11 years of age compared with children treated with placebo.

285 tients with acute myocardial infarction (MI) treated with primary percutaneous coronary intervention

286 he cultures of Saccharomyces cerevisiae were treated with pulsed electric fields (PEF) in order to ob

287 The mono- and diformylated azaBODIPYs were treated with pyrrole under mild acidic conditions follow

288 nt of prognostic groups in patients with GBM treated with radiation and temozolomide and to influence

289 Conclusion Patients with WDTC treated with RAI had an increased early risk of developi

290 Four hundred sixty-eight eyes treated with ranibizumab from randomization with gradabl

291 th Rheb-deficient CD4(+) T cells and T cells treated with rapamycin, suggesting mTORC1 signaling cont

292 ediating cellular senescence in cancer cells treated with RSV.

293 ithin 1 year reported in 27 (46.6%) patients treated with ruxolitinib vs 23 (44.2%) with BAT (P = .40

294 Furthermore, cells treated with the drug combination exhibited increased pr

295 Eos treated with the EBI2 ligands showed significantly incre

296 nse, SJSA cells (shCDK19 versus shCTRL) were treated with the p53 activator nutlin-3.

297 tect apparition of skin toxicity in patients treated with tyrosine kinase inhibitors at levels not de

298 Donor allografts from Brown Norway rats treated with University of Wisconsin (UW) solution + H2

299 kg of alkenes per tonne of suspended solids treated, with a significant reduction of sludge mass (80

300 Of the 647 treated women (mean [SD] age, 55.0 [10.8] years), 614 ha